




The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 152% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 333%, being 104% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	5,178
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,333
Liabilities, Non-Current	439
Other Assets	973
Other Compr. Net Income	0
Other Expenses	914
Other Liabilities	0
Other Net Income	7.9
Other Revenues	3.7
Property and Equipment	6,583
Research and Development	255
Selling, General and Administrative Expense	4,853

Output Variable	Value in 1000 USD
Assets	12,734
Liabilities	1,772
Expenses	6,021
Revenues	3.7
Stockholders Equity	10,962
Net Income	-6,010
Comprehensive Net Income	-6,010
BaseVar	10,269
ECR before LimitedLiability	247%
Economic Capital Ratio	333%